Focus Partners Wealth
GMAB icon

Focus Partners Wealth’s Genmab GMAB Stock Holding History

Focus Partners Wealth’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$448K Buy
16,322
+7,424
+83% +$197K ﹤0.01% 2019
2026
Q1 		$204K Buy
8,898
+2,036
+30% +$61K ﹤0.01% 2412
2025
Q4 		$211K Buy
+6,862
New +$214K ﹤0.01% 2424

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Focus Partners Wealth's GMAB Position: Q2 2026 in Review

Focus Partners Wealth increased its Genmab (GMAB) stake by 83% in Q2 2026, buying an estimated $197K and bringing the position to 16,322 shares worth $448K. The position accounts for ﹤0.01% of the portfolio, ranked #2019.

Focus Partners Wealth first reported a position in GMAB in Q4 2025 and has held it in 3 quarters since. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Focus Partners Wealth held 16,322 shares of Genmab worth $448K as of Q2 2026.
  • Focus Partners Wealth bought 7,424 Genmab shares in Q2 2026, an estimated $197K.
  • Genmab made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #2019 holding.
  • Focus Partners Wealth first reported a position in Genmab in Q4 2025 and has held it in 3 quarters since.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.